What is The Cooper Companies, Inc. (COO) DCF Fair Value and Intrinsic Value in 2026?

The Cooper Companies, Inc. (COO) intrinsic value is calculated using conservative multi-stage Discounted Cash Flow (DCF) models, 5-year free cash flow trajectories, Graham Numbers, and owner earnings multiples. LocalAlpha tracks real-time margin of safety against live market prices.

What is The Cooper Companies, Inc.'s historical Return on Invested Capital (ROIC) and Moat Rating?

The Cooper Companies, Inc. operates in the Healthcare sector (Medical Instruments & Supplies) with an economic moat rating of WIDE. LocalAlpha tracks 5-year audited quarterly ROIC, operating margin stability, and balance sheet solvency ratios.

What is The Cooper Companies, Inc.'s financial health rating and Piotroski F-Score?

The Cooper Companies, Inc.'s balance sheet quality is evaluated using the 9-point Piotroski F-Score, Altman Z-Score solvency model, debt-to-equity ratio, and quick/current liquidity coverage to guard against financial distress.

How does LocalAlpha monitor The Cooper Companies, Inc. (COO) for quarterly SEC filing thesis breaks?

LocalAlpha audits The Cooper Companies, Inc.'s 10-K, 10-Q, and 8-K regulatory filings on SEC EDGAR within 15 minutes of release. If reported metrics breach an investor's custom ROIC floor, operating margin boundary, or qualitative risk criteria, an autonomous breach audit is dispatched immediately.

StocksCOO

COO

The Cooper Companies, Inc.Healthcare / Medical Instruments & SuppliesINTACT

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

Share Price

$53.64

52W: $51.01 - $89.83

DCF Fair Value

$28.76

-86.5% Premium

Thesis Hub

P/E (TTM)

18.4x

ROIC

Operating Margin

-2.9%

FCF Yield

4.2%

Debt / Equity

0.33x

Piotroski Score

7/9

Altman Z-Score

3.61

Market Cap

$10.2B

Price vs. Intrinsic Value Corridor

Overvalued vs DCF ($28.76)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)

—()

Period Range

$— - $—

DCF Fair Value

$28.76

MOS Buy Target (-25%)

$21.57

Valuation Overlays: DCF Fair Value ($28.76) 25% MOS Buy Target ($21.57) Revised Graham ($44.01) Graham Number ($52.48)

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price

$53.64

DCF Fair Value

$28.66

-87.2% Premium

Starting Free Cash Flow ($M)$424M

$100M$424M (Reported)$50,000M

Stage 1 Growth (Years 1-5)5.3%

-5%10% (Target)35%

Stage 2 Growth (Years 6-10)4.5%

0%5%20%

Discount Rate (WACC / Hurdle)9.0%

6%9% (Standard)15% (High Risk)

Terminal Perpetual Growth2.5%

1% (GDP Floor)2.5% (Inflation)4.0%

Net Debt ($M)$2,600M

-$100B CashBalance Sheet+$150B Debt

10-Yr PV of Cash Flows

$3.5B

PV of Terminal Value

$4.6B

Implied Enterprise Value

$8.0B

Implied Equity Value

$5.4B

Year	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9	Yr 10
Projected FCF ($M)	$446	$470	$495	$521	$549	$574	$599	$626	$655	$684
Present Value (PV)	$410	$396	$382	$369	$357	$342	$328	$314	$301	$289

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-2.2% Premium

$52.48

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $2.91BVPS: $42.06

Revised Graham Formula-21.9% Premium

$44.01

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Growth Rate (g%)

Bond Yield (Y%)

Buffett Owner Earnings4% Yield

$2.12 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $0.4BYield: 4%

Reverse DCF: Market Growth Expectation

FAIR BARRIER

8.1% CAGR (Next 10 Yrs)

At the current price of $53.64, the market is assuming the business will compound Free Cash Flow at 8.1% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict

ℹ Fair expectations: Requires steady execution.

Autonomous Thesis Underwriting

Surveil COO with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for The Cooper Companies, Inc.. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin -2.9% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Track COO & Set Alerts Browse S&P 500 Coverage

Frequently Asked Questions: The Cooper Companies, Inc. (COO) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for The Cooper Companies, Inc..

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, The Cooper Companies, Inc. has an estimated DCF intrinsic fair value of $28.76 per share compared to its current market price of $53.64. This represents an estimated 86.5% premium over fair value. Additionally, its classic Benjamin Graham Number stands at $52.48.